Introduction to Medical Decision Making and Decision Analysis

Slides:



Advertisements
Similar presentations
Health Economics for Prescribers
Advertisements

Modeling and Simulation By Lecturer: Nada Ahmed. Introduction to simulation and Modeling.
Markov Models: Overview Gerald F. Kominski, Ph.D. Professor, Department of Health Services.
Cost-Effectiveness Using Decision-Analytic Models
Managerial Decision Modeling with Spreadsheets
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Decision Analysis Prof. Carl Thompson
“ Building Strong “ Delivering Integrated, Sustainable, Water Resources Solutions Probabilistic Scenario Analysis Institute for Water Resources 2010 Charles.
Engineering Economic Analysis Canadian Edition
Approaches to Data Acquisition The LCA depends upon data acquisition Qualitative vs. Quantitative –While some quantitative analysis is appropriate, inappropriate.
1 Cost-effectiveness analysis using Markov modeling Rahul Ganguly Ph.D. November 25 th, 2006 BITS, Pilani.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Introduction to decision modelling Andrew Sutton.
Planning under Uncertainty
Decision Analysis Your Logo Here Jane Hagstrom University of Illinois Jane Hagstrom University of Illinois.
Engineering Economics in Canada Chapter 12 Dealing with Risk: Probability Analysis.
Decision Modeling Techniques HINF Medical Methodologies Session 3.
FIN 685: Risk Management Topic 5: Simulation Larry Schrenk, Instructor.
The Rational Decision-Making Process
Introduction to Decision Analysis
Marakas: Decision Support Systems, 2nd Edition © 2003, Prentice-Hall Chapter Chapter 4: Modeling Decision Processes Decision Support Systems in the.
Simulation.
2-1 Sample Spaces and Events Conducting an experiment, in day-to-day repetitions of the measurement the results can differ slightly because of small.
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
1 Chapter 3 Structuring Decision. 2 Structuring Decisions Learning Objectives Fundamental steps in model creation Identify and structure values and objectives.
Problem A newly married couple plans to have four children and would like to have three girls and a boy. What are the chances (probability) their desire.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 16: Economic Evaluation using Decision.
MAKING COMPLEX DEClSlONS
Deciding when to intervene: A Markov Decision Process approach Xiangjin Zou(Rho) Department of Computer Science Rice University [Paolo Magni, Silvana Quaglini,
1 Performance Evaluation of Computer Networks: Part II Objectives r Simulation Modeling r Classification of Simulation Modeling r Discrete-Event Simulation.
Introduction to TreeAge June 1, 2005 Mendel E. Singer, Ph.D. Case School of Medicine
Value of information Marko Tainio Decision analysis and Risk Management course in Kuopio
1 ECGD4214 Systems Engineering & Economy. 2 Lecture 1 Part 1 Introduction to Engineering Economics.
Engineering Economic Analysis Canadian Edition
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
BINOMIALDISTRIBUTION AND ITS APPLICATION. Binomial Distribution  The binomial probability density function –f(x) = n C x p x q n-x for x=0,1,2,3…,n for.
MBA7025_01.ppt/Jan 13, 2015/Page 1 Georgia State University - Confidential MBA 7025 Statistical Business Analysis Introduction - Why Business Analysis.
Integrated Risk Management Charles Yoe, PhD Institute for Water Resources 2009.
Advanced Project Management Project Risk Management Ghazala Amin.
Outline of Chapter 9: Using Simulation to Solve Decision Problems Real world decisions are often too complex to be analyzed effectively using influence.
MBA7020_01.ppt/June 13, 2005/Page 1 Georgia State University - Confidential MBA 7020 Business Analysis Foundations Introduction - Why Business Analysis.
PHARMACOECONOMIC EVALUATIONS & METHODS MARKOV MODELING IN DECISION ANALYSIS FROM THE PHARMACOECONOMICS ON THE INTERNET ®SERIES ©Paul C Langley 2004 Maimon.
Simulation is the process of studying the behavior of a real system by using a model that replicates the system under different scenarios. A simulation.
Probabilistic Scenario Analysis Institute for Water Resources 2009 Charles Yoe, PhD
Introduction to Probabilistic Analysis Introduction to Probabilistic Analysis The third phase of the cycle incorporates uncertainty into the analysis.
Decision Analytic Approaches for Evidence-Based Practice M8120 Fall 2001 Suzanne Bakken, RN, DNSc, FAAN School of Nursing & Department of Medical Informatics.
1 1 Slide Simulation Professor Ahmadi. 2 2 Slide Simulation Chapter Outline n Computer Simulation n Simulation Modeling n Random Variables and Pseudo-Random.
OPERATING SYSTEMS CS 3530 Summer 2014 Systems and Models Chapter 03.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
QUANTITATIVE TECHNIQUES
DECISION MAKING TOOLS 1. Elements of Decision Problems 2.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
EBM --- Journal Reading Presenter :葉麗雯 Date : 2005/10/27.
Research Design Evidence Based Medicine Concepts and Glossary.
Introduction to decision analysis modeling Alice Zwerling, Postdoctoral fellow, JHSPH McGill TB Research Methods Course July 7, 2015.
Course: Research in Biomedicine and Health III Seminar 5: Critical assessment of evidence.
Csci 418/618 Simulation Models Dr. Ken Nygard, IACC 262B
Business Modeling Lecturer: Ing. Martina Hanová, PhD.
Alcohol and hospital admissions for injury and alcohol poisoning in West Sussex– a second order Monte Carlo simulation Ross Maconachie Public Health WSCC.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
1 Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID Health Care Improvement Project, University Research Co., LLC
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
Introduction to Medical Decision Making and Decision Analysis Jeremy D. Goldhaber-Fiebert, PhD Presented October 24, 2012.
IE 485 «Decision Making in Health Care»
6. Risk Analysis for the New Venture Using Monte Carlo Simulation
Business Modeling Lecturer: Ing. Martina Hanová, PhD.
Operations Management
Health care decision making
SIMULATION IN THE FINANCE INDUSTRY BY HARESH JANI
Presentation transcript:

Introduction to Medical Decision Making and Decision Analysis Gillian D. Sanders Ph.D. Duke Clinical Research Institute Duke University July 18, 2007

Outline Decision analysis Markov models Components of decision analysis Building a tree: Example Sensitivity analyses Markov models Background Constructing the model Example Monte Carlo simulations

Decision Analysis Decision analysis is a quantitative, probabilistic method for modeling problems under situations of uncertainty

Making a Decision We make a decision when we irreversibly allocate resources. We typically use the following steps: gather information assess consequences of the alternatives take an action Goal of decision analysis is to clarify the dynamics and trade-offs involved in selecting one strategy from a set of alternatives Usually, in everyday decision-making, we do not take the time to thoroughly analyze the decision

Decision Analysts Deliberately seek out new, creative alternatives Identify the possible outcomes Identify relevant uncertain factors Encode probabilities for the uncertain factors Specify the value placed on each outcome Formally analyze the decision.

Decisions Vary in Degree Of: Complexity -- large number of factors, multiple attributes, more than one decision-maker Time factor -- static (no change over time) vs. dynamic (time-dependent) Uncertainty -- deterministic vs. probabilistic. Deterministic means there is no uncertainty and the problem can be solved with a set of precise equations

Decision Analysis is Most Helpful For important, unique, complex, nonurgent, and high-stakes decisions that involve uncertainty “Decision Analysis = Decision Therapy.” A great deal of work is done to decompose the decision problem, work out the relation between factors, specify probabilities for uncertain events, and identify what is at stake and how it might be affected by the decision Constructing the tree, even before “solving” it mathematically, can provide important insights.

Cost-Effectiveness Analyses Cost-effectiveness analysis (CEA) is a methodology for evaluating the tradeoffs between health benefits and costs CEA is aid to decision making, not a complete resource allocation procedure

Cost-Effectiveness Ratio Compares a specific (new) intervention to a stated alternative (old) intervention Costnew – Costold / Benefitnew – Benefitold Incremental resources required by the intervention Incremental health effects gained by using the intervention

Decision Model Schematic representation of all the clinical important outcomes of a decision. Used to combine knowledge about decision problem from many sources Computes average outcomes (e.g., QALYs, costs, etc.) from decisions.

Elements of Decision Analysis Structure the problem Identify decision alternatives List possible clinical outcomes Represent sequence of events Assign probabilities to all chance events Assign utility, or value, to all outcomes Evaluate the expected utility of each strategy Perform sensitivity analyses

Structuring the Problem Decision model (usually decision tree) is chosen to represent the clinical problem Model needs to be simple enough to be understood, but complex enough to capture the essentials of the problem Need to make a series of assumptions for modeling

Decision Node: A point in a decision tree at which several choices are possible. The decision maker controls which is chosen. operate Only 2 choices shown here. But can have more, as long as they are mutually exclusive do not operate

Chance Node: A point in a decision tree at which chance determines which outcome will occur. disease present Only 2 outcomes shown here. But can have more, as long as they are mutually exclusive and collectively exhaustive disease absent

Some Definitions Mutually exclusive Collectively exhaustive The intersection of the events is empty One (and only one) of the events must occur Collectively exhaustive Events taken together make up the entire outcome space At least one of the events must occur

Terminal Node: Final outcome state associated with each possible pathway 20 LY Some measure of value or worth needs to be applied to the terminal nodes (eg. LYs, QALYs, costs) Patient cured

Outline Decision analysis Markov models Components of decision analysis Building a tree: Example Sensitivity analyses Markov models Background Constructing the model Example Monte Carlo simulations

Example Symptomatic patient: operate (risky) medical management If disease present at surgery, must decide whether try for cure or palliate Want to evaluate surgery vs. medical management

cure survive try cure no cure disease present operative death surgery survive cure survive disease absent palliate no cure operative death operative death cure disease present drug no cure disease absent

Each path through the tree defines a unique potential result. cure survive try cure no cure disease present operative death surgery survive cure survive disease absent palliate no cure operative death operative death cure disease present 1. Decide to operate 2. Find disease at surgery drug no cure 3. Try for surgical cure 4. Patient survives surgery disease absent 5. Surgery unsuccessful

Insert probabilities at each chance node Insert probabilities at each chance node. Sources include data from literature/studies, modeling, expert judgment... cure survive 90% 90% try cure 10% no cure disease present 10% operative death 10% surgery survive cure survive 10% 90% 99% disease absent 98% 90% 1% palliate no cure operative death 2% operative death cure disease present 10% 90% 10% drug no cure 90% disease absent

Assign a value to the outcome at each endpoint cure Assign a value to the outcome at each endpoint 20 LY survive 90% 90% try cure 10% no cure disease present 2 LY 10% operative death 0 LY 10% surgery survive cure survive 10% 90% 99% disease absent 98% 90% 1% palliate no cure operative death 2% operative death cure disease present 10% AVERAGE OUTCOMES Operative death: 0 life years Death from progression of the disease: 2 life years Cure: 20 life years 90% 10% drug no cure 90% disease absent

Compute average results, working right to left… cure Compute average results, working right to left… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive cure 20 LY 20 LY survive 10% 90% 99% disease absent 98% 90% 1% palliate no cure operative death 2 LY 0 LY 2% operative death 0 LY cure 20 LY disease present 10% Average LYs here: = 10% x 20 + 90% x 2 =.1x20 + .9x2 = 2.0 + 1.8 = 3.8 LY 90% 10% drug no cure 2 LY 90% disease absent 20 LY

Replace these chance nodes with the average… cure Replace these chance nodes with the average… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive cure 20 LY 20 LY survive 10% 90% 99% disease absent 98% 90% 1% palliate no cure operative death 2 LY 0 LY 2% operative death 0 LY disease present Average LYs here: = 10% x 20 + 90% x 2 =.1x20 + .9x2 = 2.0 + 1.8 = 3.8 LY 3.8 LY 10% drug 90% disease absent 20 LY

Replace these chance nodes with the average… cure Replace these chance nodes with the average… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive 20 LY survive 90% 99% 3.8 LY disease absent 98% 1% palliate operative death 0 LY 2% operative death 0 LY disease present Average LYs here: = 10% x 20 + 90% x 2 =.1x20 + .9x2 = 2.0 + 1.8 = 3.8 LY 3.8 LY 10% drug 90% disease absent 20 LY

Replace next chance node with the average… cure Replace next chance node with the average… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive 20 LY survive 90% 99% 3.8 LY disease absent 98% 1% palliate operative death 0 LY 2% operative death 0 LY disease present Average LY here: = 10% x 3.8 + 90% x 20 =.1x3.8 + .9x20 = .38 + 18 = 18.38 LY 3.8 LY 10% drug 90% disease absent 20 LY

Replace next chance node with the average… cure Replace next chance node with the average… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive 20 LY survive 90% 99% 3.8 LY disease absent 98% 1% palliate operative death 0 LY 2% operative death 0 LY Average LY here: = 10% x 3.8 + 90% x 20 =.1x3.8 + .9x20 = .38 + 18 = 18.38 LY drug 18.38 LY

Continue this process… cure Continue this process… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive 20 LY survive 90% 99% 3.8 LY disease absent 98% 1% palliate operative death 0 LY 2% operative death 0 LY Average LY here: = 98% x 3.8 + 2% x 0 =.98x 3.8 + .02 x 0 = 3.72 + 0 = 3.72 LY drug 18.38 LY

Continue this process… cure Continue this process… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive 20 LY 90% 99% disease absent 1% palliate operative death 3.72 LY 0 LY Average LY here: = 98% x 3.8 + 2% x 0 =.98x 3.8 + .02 x 0 = 3.72 + 0 = 3.72 LY drug 18.38 LY

Continue this process… cure Continue this process… 20 LY survive 90% 90% try cure 10% no cure disease present 10% 2 LY operative death 0 LY 10% surgery survive 20 LY 90% 99% disease absent 1% palliate operative death 3.72 LY 0 LY Average LY here: = 90% x 20 + 10% x2 =.90x 20 + .1 x 2 = 18 + .2 = 18.2 LY drug 18.38 LY

Continue this process… survive 18.2 LY 90% try cure disease present 10% operative death 0 LY 10% surgery survive 20 LY 90% 99% disease absent 1% palliate operative death 3.72 LY 0 LY Average LY here: = 90% x 20 + 10% x2 =.90x 20 + .1 x 2 = 18 + .2 = 18.2 LY drug 18.38 LY

Continue this process… survive 18.2 LY 90% try cure disease present 10% operative death 0 LY 10% surgery survive 20 LY 90% 99% disease absent 1% palliate operative death 3.72 LY 0 LY Average LY here: = 90% x 18.2 + 10% x0 =.90x 18.2+ .1 x0 = 16.38 + 0 = 16.38 LY drug 18.38 LY

Continue this process… try cure 16.38 LY disease present 10% surgery survive 20 LY 90% 99% disease absent 1% palliate operative death 3.72 LY 0 LY Average LY here: = 90% x 18.2 + 10% x0 =.90x 18.2+ .1 x0 = 16.38 + 0 = 16.38 LY drug 18.38 LY

try cure disease present 10% surgery survive 90% 99% disease absent 16.38 LY disease present 10% surgery survive 20 LY 90% 99% disease absent 1% palliate operative death 3.72 LY 0 LY At a Decision Node you choose which path you wish to take -- no averaging! drug Here, we would choose to try for cure -- obviously! 18.38 LY

disease present try cure 10% surgery survive 90% 99% disease absent 1% 16.38 LY 10% surgery survive 20 LY 90% 99% disease absent 1% operative death 0 LY drug 18.38 LY

Continue working from right to left, averaging out at Chance Nodes, and choosing best branch at Decision Nodes... disease present try cure 16.38 LY 10% surgery survive 20 LY 90% 99% disease absent 1% operative death 0 LY Average LY here: = 99% x 20 + 1% x0 =.99x 20+ .01 x0 = 19.8 + 0 = 19.8 LY drug 18.38 LY

disease present try cure 10% surgery 90% disease absent drug 16.38 LY Average LY here: = 99% x 20 + 1% x0 =.99x 20+ .01 x0 = 19.8 + 0 = 19.8 LY drug 18.38 LY

disease present try cure 10% surgery 90% disease absent drug 16.38 LY Average LY here: =10% x 16.38 + 90% x19.8 =.1x 16.38 + .9 x19.8 = 1.638 + 17.82 = 19.46 LY drug 18.38 LY

surgery drug 19.46 LY Average LY here: =10% x 16.38 + 90% x19.8 = 1.638 + 17.82 = 19.46 LY drug 18.38 LY

The outcome for each decision is more apparent now: surgery Surgery (intending cure) produces average of 19.46 LY 19.46 LY The incremental benefit of Surgery versus Medical Management is 19.46 - 18.38 = 1.08 LY drug 18.38 LY Medical management yields an average of 18.38 LY

Repeat this Decision Analysis Using Other Outcome Measures Instead of just using average life years, can use QALYs at each endpoint. If you use both costs and QALYs at each endpoint: Then can calculate the incremental cost effectiveness of surgery versus medical management

Outline Decision analysis Markov models Components of decision analysis Building a tree: Example Sensitivity analyses Markov models Background Constructing the model Example Monte Carlo simulations

Sensitivity Analysis Systematically asking “what if” questions to see how the decision result changes. Determines how “robust” the decision is. Threshold analysis: one parameter varied Multi-way analysis: multiple parameters systematically varied

Sensitivity Analysis: Probability of Operative Death Threshold Base Case

Two-Way Sensitivity Analysis: pDisease vs. pOperativeDeath Choose Drug Choose Surgery

Outline Decision analysis Markov models Components of decision analysis Building a tree: Example Sensitivity analyses Markov models Background Constructing the model Example Monte Carlo simulations

What is a Markov Model? Mathematical modeling technique, derived from matrix algebra, that describes the transitions a cohort of patients make among a number of mutually exclusive and exhaustive health states during a series of short intervals or cycles

When to use a Markov Model? Problem involves risk that is continuous over time Timing of events is important Important events may happen more than once

Properties of a Markov Model Patient is always in one of a finite number of health states Events are modeled as transitions from one state to another Contribution of utility to overall prognosis depends on length of time spent in health states During each cycle, the patient may make a transition from one state to another

Outline Decision analysis Markov models Components of decision analysis Building a tree: Example Sensitivity analyses Markov models Background Constructing the model Example Monte Carlo simulations

Constructing a Markov Model Choose set of mutually exclusive health states Determine possible transitions between these health states State transitions Transition probabilities Determine clinical valid cycle length

Cycle Length Clinically meaningful time interval Entire life of patient, relatively rare events  yearly Shorter time frame, frequent events, rate changing rapidly over time  monthly or weekly Availability of probability data?

Markovian Assumption Behavior of the process subsequent to any cycle depends only on its description in that cycle No memory of earlier cycles How do we get around this? New health states Tunnel states

Outline Decision analysis Markov models Components of decision analysis Building a tree: Example Sensitivity analyses Markov models Background Constructing the model Example Monte Carlo simulations

State Transition Diagram WELL SICK DEAD

Evaluation Compute number of cycles spent in each health state Expected utility = Define incremental utility for spending a cycle in given health state

State Transition Diagram WELL u = 1.0 SICK u = 0.7 t = 2.5 cycles t = 1.25 cycles DEAD u = 0

Quality-adjusted life expectancy. = (tw. uw) + (ts. us). = (2. 5 Quality-adjusted life expectancy = (tw * uw) + (ts * us) = (2.5 * 1) + (1.25 * 0.7) = 3.9 QALYs

Calculation of Outcomes with a Markov Model Assume absorbing health state (death) Methods: Matrix algebraic solution Markov cohort simulation Monte Carlo simulation

Fundamental Matrix Solution Requires constant transition probabilities Does not require simulation Requires matrix algebra

Transition Probability Matrix Well Sick Dead Well 0.75 0.20 0.05 Sick 0 0.70 0.30 Dead 0 0 1 Starting Probability Vector: [ 1 0 0 ]

Markov Cohort Simulation Large number of patients are followed as a cohort Time dependent probabilities and utilities may be easily incorporated into the analysis Does not provide information on the distribution or variance of expected values

Markov Cohort Simulation Time t Well Sick Dead Well Sick Dead t+1

Markov Cohort Simulation Time t Well Sick Dead 0.05 0.30 1.0 0.75 0.20 0.70 Well Sick Dead t+1

Markov Cohort Simulation Time t Well Sick Dead 0.05 0.30 1.0 0.75 0.20 0.70 Well Sick Dead t+1 Cycle (allows time dependence)

Quality-of-Life Adjustments 1.0 0.5 0.0 Well Sick Dead

Expressed as a Markov Tree: Structure Stay Well Well Well Get Sick Sick Die Dead Stay Sick Sick Markov Sick Die Dead Dead Dead

Expressed as a Markov Tree: Transition Probabilities Stay Well Well 0.75 Well Get Sick Sick 0.20 1 Die Dead 0.05 Stay Sick Sick Markov Sick 0.70 Die Dead 0.30 Dead Dead

Expressed as a Markov Tree: Utilities Stay Well Well = 1.0 0.75 Well Get Sick Sick = 0.5 0.20 1 Die Dead = 0 0.05 Stay Sick Sick = 0.5 Markov Sick 0.70 Die Dead = 0 0.30 Dead Dead = 0

Running the Model Cycle Total Cycle Well Sick Dead Reward Reward 0 1 0 0 0.5 0.5 1 0.75 0.20 0.05 0.85 1.35 2 0.56 0.29 0.15 0.71 2.06 3 0.42 0.32 0.26 0.58 2.64 4 0.32 0.31 0.38 0.47 3.11

Outline Decision analysis Markov models Components of decision analysis Building a tree: Example Sensitivity analyses Markov models Background Constructing the model Example Monte Carlo simulations

Monte Carlo Simulation Determines the prognoses of a large number of individual patients Each patient runs through model until death – repeat large number of times (~104) Provides a distribution of survival Standard deviation Variance

Monte Carlo Simulation Well Sick Dead 1 Well Sick Dead 2 Sick Dead Well 3 WWSD Sick Dead Well 4

Probabilistic Sensitivity Analysis (2nd order Monte Carlo) Decision tree estimates of probabilities and utilities are replaced with probability distributions (e.g. logistic-normal) The tree is evaluated many times with random values selected from each distribution Results include means and standard deviations of the expected values of each strategy

Characteristics of Markov Approaches Feature Markov Cohort Monte Carlo Matrix Transition Probabilities Time-dependent Constant Incremental Utilities Accuracy Dependent on cycle length Dependent on number of trials Cycle-independent Computation Moderate Most Least Variability Measures No Yes

Some Things to Remember Use of Markov models are appropriate in a number of situations Tradeoff between simplicity of conventional decision tree versus fidelity of Markov process When using decision trees OR Markov trees: Assumptions and input variables should be as transparent as possible Adequate sensitivity analysis should be performed Modeling as well as clinical expertise should be consulted

Summary: Medical Decision Analysis Clearly defines alternatives, events, and outcomes Formal method to combine evidence Can prioritize information acquisition Can help healthcare providers to make medical decisions under uncertainty

Decision Analysis Software Decision Maker http://infolab.umdnj.edu/windm/ DATA by TreeAge http://www.treeage.com Excel spreadsheet models Other software packages

Where To Go For More Sox HC, Blatt MA, Higgins MC, Marton KI (1988) Medical Decision Making. Boston MA: Butterworth-Heinemann Publisher. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Parts 1-5. Med Decis Making. 1997;17(2):123-159. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-38. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419-458. Society for Medical Decision Making (http://www.smdm.org)